6.06BMarket Cap
LossP/E TTM
Xenon Pharmaceuticals Inc
Key Figures
63.940Open
64.505High
736.96KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.76%Turnover Ratio
64.190Prev. Close
62.560Low
33.76MTurnover
LossP/E Static
4.53P/B
0.00%Div Yield TTM
-35.98%ROA
63.95052wk High
1.23Volume Ratio
-234.33MNet Profit
96.62MShares
-4.7092EPS TTM
0.63Beta
-37.53%ROE
28.19052wk Low
3.03%Amplitude
100.00%Gross Margin
6.06BMarket Cap
2.80Reward/Risk
2.15%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Xenon Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 20 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 80.12.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Xenon Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Xenon Pharmaceuticals Inc Highlights
StrengthsRisks
Xenon Pharmaceuticals Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Xenon Pharmaceuticals Inc
XENE
20
Ionis Pharmaceuticals Inc
IONS
26
Kymera Therapeutics Inc
KYMR
23
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Xenon Pharmaceuticals Inc Info
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
Ticker SymbolXENE
CompanyXenon Pharmaceuticals Inc
CEOMortimer (Ian C)
Websitehttps://www.xenon-pharma.com/
Shareholders
FAQs
What is the current price of Xenon Pharmaceuticals Inc (XENE)?
The current price of Xenon Pharmaceuticals Inc (XENE) is 62.67.
What is the symbol of Xenon Pharmaceuticals Inc?
The ticker symbol of Xenon Pharmaceuticals Inc is XENE.
What is the 52-week high of Xenon Pharmaceuticals Inc?
The 52-week high of Xenon Pharmaceuticals Inc is 63.95.
What is the 52-week low of Xenon Pharmaceuticals Inc?
The 52-week low of Xenon Pharmaceuticals Inc is 28.19.
What is the market capitalization of Xenon Pharmaceuticals Inc?
The market capitalization of Xenon Pharmaceuticals Inc is 6.06B.
Is Xenon Pharmaceuticals Inc (XENE) currently rated as Buy, Hold, or Sell?
According to analysts, Xenon Pharmaceuticals Inc (XENE) has an overall rating of Buy, with a price target of 80.12.
What is the Earnings Per Share (EPS TTM) of Xenon Pharmaceuticals Inc (XENE)?
The Earnings Per Share (EPS TTM) of Xenon Pharmaceuticals Inc (XENE) is -4.36.
